Answers are grounded in this paper and cite their sources.
Benzodiazepine hypnotics (BZDs) have been a popular treatment for insomnia since the 1960s, but they have various problematic side effects, including falls and delirium.1, 2 Non-BZDs were developed right after BZDs and are BZD receptor agonists (BZD-RAs) in action. In Japan, two other non-BZD-RA hypnotics were released, namely ramelteon (melatonin receptor agonist [MRA]) in 2010 and suvorexant (orexin receptor antagonist [ORA]) in 2014. Despite the existence of these non-BZD-RAs, according to an analysis using Medical Data Vision (MDV), 96.5% of the first-prescribed sleep medications to Japanese insomnia patients in Japan (from 2012 to 2016) were BZD-RAs.3 American studies reported similar trends during 1999–2010.4 In 2020, the US Food and Drug Administration (FDA) issued a warning about the risks of BZD-RAs.5 Lemborexant, a novel ORA, was launched in 2020 in Japan. A relatively high proportion (66.7%) of patients across different groups can reportedly completely switch from BZD-RAs to lemborexant.6, 7 This study investigated hypnotic prescription trend changes in Japan following the FDA warning and the launch of lemborexant, which can replace BZD-RAs. The study included inpatients and outpatients enrolled in the MDV analyzer, a hospital-based claims database, from December 1, 2012 to November 30, 2021. The MDV analyzer contains anonymized claims data from 430 diagnosis–procedure combination hospitals and the total number of patients was 38.5 million (including deceased patients) as of October 31, 2021. This study included the following pharmaceuticals: BZDs estazolam, quazepam, triazolam, nitrazepam, haloxazolam, flunitrazepam, flurazepam, brotizolam, rilmazafone hydrochloride hydrate, and lormetazepam, non-BZDs eszopiclone, zopiclone, and zolpidem tartrate, the only MRA was ramelteon, and the ORAs suvorexant and lemborexant. The annual change in rates of patients prescribed each hypnotic was analyzed using the Cochran Armitage trend test, and data from 2021 were analyzed using the χ2 test. For convenience, data from December of the previous year to November of the current year were treated as data for the current year. Patients who were prescribed two or more hypnotics were counted for each drug. From 2013 to 2021, hypnotic prescription rates changed nonsignificantly (2013 7.97%, 2021 7.98%; P = 0.9309), BZD prescriptions decreased significantly (2013 5.0%, 2021 2.9%; P < 0.0001), MRA (2013 0.3%, 2021 0.9%; P < 0.0001) and ORA (2013 0.0%, 2021 2.7%; P < 0.0001; Figure 1a) prescriptions increased significantly, and non-BZD prescriptions changed nonsignificantly (2013 3.5%, 2021 3.3%; P = 0.5462). The absolute number of prescriptions for each hypnotic is shown in Table S1. In 2021, hypnotic prescription rates were higher in patients aged 65 years and older (14.5%) than in those younger than 65 years (5.0%), in inpatients (33.5%) than in outpatients (4.5%), and in women (9.7%) than in men (9.4%) (all P < 0.0000001). When comparing prescription rates of different hypnotics in 2021 between those aged 65 years and older and those younger than 65 years, the former group showed lower rates for BZDs and non-BZDs, and higher rates for the MRA and ORAs (all P < 0.0000001; Figure 1b). When comparing these rates between inpatients and outpatients, inpatients showed lower rates for BZDs and non-BZDs and higher rates for the MRA and ORAs (all P < 0.0000001; Figure 1b). When comparing these rates between men and women, men showed lower rates for BZDs and non-BZDs and higher rates for the MRA and ORAs (all P < 0.0000001; Figure 1b). These results suggest that prescription rates for hypnotics are shifting from BZDs to MRAs and ORAs in Japan, although general hypnotic prescription rates remain similar. Hospitalized patients and older adults have a higher risk of experiencing some side effects (e.g., delirium and falls) of hypnotics,8, 9 and the high prescribing rates of the MRA and ORAs in our sample, especially for hospitalized patients and older adults, may indicate that the risks of hypnotics are becoming more widely recognized. Meanwhile, the issues that remain to be addressed in the near future are the prescription rates of non-BZDs, which remained mostly unchanged, and of BZDs, which were prescribed more to women than to men, despite the intake of BZDs being known to be a risk in the perinatal period.10 It would be desirable for Japanese practitioners to actively switch to ORA prescriptions not only for first-prescribed drugs but also for patients already prescribed BZDs. Regarding study limitations, first, it was retrospective and observational, with reliance on a single database; the MDV was designed for patients treated at large acute-care hospitals in Japan, so the results cannot be generalized to patients from other medical facilities. Second, the lack of data linkage between medical facilities in the MDV means that patients who were prescribed hypnotics at more than one facility may be included as separate patients. K.U. and E.S. designed the study, performed statistical analyses, analyzed and interpreted the data, and drafted and edited the manuscript. D.K., N.O., and K.M. collected the data. R.O., T.W., and K.O. performed the drafting and editing, and contributed to supervision. All authors read and approved the final manuscript. None. Eiji Suzuki received research grants from Eisai Co., Ltd. and Shionogi & Co., Ltd. Kensuke Usui, Daisuke Kikuchi, Noa Otsuka, Kouta Miyagi, Ryusuke Ouchi, Takashi Watanabe, and Kouji Okada have no conflicts of interest that are directly relevant to the content of this article. None This study conducted a retrospective analysis of data using a nationwide claims database managed by Medical Data Vision Co., Ltd., Tokyo, Japan. Because the data analyzed are anonymized and there was no direct patient involvement, ethical approval and patient consent was waived by the relevant institutional review boards. Medical Data Vision is a company that collects and uses patients' personal data, which are then anonymously processed in accordance with regulations laid down in the Japanese Act on the Protection of Personal Information and the European Union's General Data Protection Regulation. N/A N/A N/A Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Usui et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: